Latest period
$5.28B
YoY change
+112.3%
5Y CAGR
+14.6%
Peak year (2017)
$8.03B
Latest annual
$7.27B
Cash on Hand history chart for Eli Lilly (LLY) from 1985 to 2025
Latest: $7.27B
Cash on Hand growth chart for Eli Lilly (LLY) from 1985 to 2025
Latest: +112.3%
Cash on Hand history table for Eli Lilly (LLY) from 1985 to 2025
| 2025 | $7.27B | +112.3% | +$3.84B | ||
| 2024 | $3.42B | +16.9% | +$495.50M | ||
| 2023 | $2.93B | +32.4% | +$715.90M | ||
| 2022 | $2.21B | -43.4% | −$1.70B | ||
| 2021 | $3.91B | +6.2% | +$227.30M | ||
| 2020 | $3.68B | +51.0% | +$1.24B | ||
| 2019 | $2.44B | -67.1% | −$4.97B | ||
| 2018 | $7.41B | -7.8% | −$625.20M | ||
| 2017 | $8.03B | +33.0% | +$2.00B | ||
| 2016 | $6.04B | +35.6% | +$1.59B | ||
| 2015 | $4.45B | -7.8% | −$375.20M | ||
| 2014 | $4.83B | -10.6% | −$570.30M | ||
| 2013 | $5.40B | -5.0% | −$287.00M | ||
| 2012 | $5.68B | -17.6% | −$1.21B | ||
| 2011 | $6.90B | +2.5% | +$170.10M | ||
| 2010 | $6.73B | +49.6% | +$2.23B | ||
| 2009 | $4.50B | -24.1% | −$1.43B | ||
| 2008 | $5.93B | +22.7% | +$1.09B | ||
| 2007 | $4.83B | +24.2% | +$940.20M | ||
| 2006 | $3.89B | -22.8% | −$1.15B | ||
| 2005 | $5.04B | -32.5% | −$2.43B | ||
| 2004 | $7.46B | +101.0% | +$3.75B | ||
| 2003 | $3.71B | +1.6% | +$58.60M | ||
| 2002 | $3.65B | -2.0% | −$76.30M | ||
| 2001 | $3.73B | -19.2% | −$887.20M | ||
| 2000 | $4.62B | +20.4% | +$782.20M | ||
| 1999 | $3.84B | +156.5% | +$2.34B | ||
| 1998 | $1.50B | -23.2% | −$451.80M | ||
| 1997 | $1.95B | +139.3% | +$1.13B | ||
| 1996 | $813.70M | -18.6% | −$185.80M | ||
| 1995 | $999.50M | +86.2% | +$462.60M | ||
| 1994 | $536.90M | -0.5% | −$2.70M | ||
| 1993 | $539.60M | +24.8% | +$107.20M | ||
| 1992 | $432.40M | -9.8% | −$46.80M | ||
| 1991 | $479.20M | +36.8% | +$129.00M | ||
| 1990 | $350.20M | +8.4% | +$27.20M | ||
| 1989 | $323.00M | -57.6% | −$438.50M | ||
| 1988 | $761.50M | -26.1% | −$269.40M | ||
| 1987 | $1.03B | +112.1% | +$544.90M | ||
| 1986 | $486.00M | +19.7% | +$79.90M | ||
| 1985 | $406.10M | — | — |
- 2025$7.27B+112.3%
- 2024$3.42B+16.9%
- 2023$2.93B+32.4%
- 2022$2.21B-43.4%
- 2021$3.91B+6.2%
- 2020$3.68B+51.0%
- 2019$2.44B-67.1%
- 2018$7.41B-7.8%
- 2017$8.03B+33.0%
- 2016$6.04B+35.6%
- 2015$4.45B-7.8%
- 2014$4.83B-10.6%
- 2013$5.40B-5.0%
- 2012$5.68B-17.6%
- 2011$6.90B+2.5%
- 2010$6.73B+49.6%
- 2009$4.50B-24.1%
- 2008$5.93B+22.7%
- 2007$4.83B+24.2%
- 2006$3.89B-22.8%
- 2005$5.04B-32.5%
- 2004$7.46B+101.0%
- 2003$3.71B+1.6%
- 2002$3.65B-2.0%
- 2001$3.73B-19.2%
- 2000$4.62B+20.4%
- 1999$3.84B+156.5%
- 1998$1.50B-23.2%
- 1997$1.95B+139.3%
- 1996$813.70M-18.6%
- 1995$999.50M+86.2%
- 1994$536.90M-0.5%
- 1993$539.60M+24.8%
- 1992$432.40M-9.8%
- 1991$479.20M+36.8%
- 1990$350.20M+8.4%
- 1989$323.00M-57.6%
- 1988$761.50M-26.1%
- 1987$1.03B+112.1%
- 1986$486.00M+19.7%
- 1985$406.10M—
Cash on Hand values are taken from Eli Lilly's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Cash on Hand at Eli Lilly (LLY)
According to Eli Lilly's latest reported financial statements, the company's latest reported cash and short-term investments is $5.28B. Cash on hand here is cash, cash equivalents, and short-term investments reported at the end of each period — the most liquid assets on the balance sheet. Compare with total debt for net leverage and total assets for the share of assets held in cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, Eli Lilly (LLY) cash and short-term investments totalled $7.27B – surged 112.3% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Eli Lilly cash and short-term investments compounded at +14.6% per year, sustaining 3 straight years of year-over-year growth.
Between 2017 and 2025, Eli Lilly cash and short-term investments declined 9.5%, falling from $8.03B to $7.27B.
The highest annual cash and short-term investments of $8.03B was reported in 2017. The lowest in the available history was $323.00M in 1989.
Eli Lilly Cash on Hand by Year
Eli Lilly Cash on Hand 2025: $7.27B
Eli Lilly posted cash and short-term investments of $7.27B in 2025, surged 112.3% from 2024.
Eli Lilly Cash on Hand 2024: $3.42B
In 2024, Eli Lilly reported cash and short-term investments of $3.42B, grew 16.9% from 2023.
Eli Lilly Cash on Hand 2023: $2.93B
Eli Lilly cash and short-term investments in 2023 was $2.93B, surged 32.4% from 2022.
Eli Lilly Cash on Hand 2022: $2.21B
2022's cash and short-term investments for Eli Lilly came in at $2.21B, plunged 43.4% below 2021.
Eli Lilly Cash on Hand 2021: $3.91B
Eli Lilly cash and short-term investments in 2021 was $3.91B.
See more financial history for Eli Lilly (LLY).
Sector peers by Cash on Hand
Healthcare peers of Eli Lilly (LLY), ranked by their latest cash and short-term investments
| $28.12B | |
| $20.10B | |
| $14.56B | |
| $10.11B | |
| $9.13B | |
| $5.74B | |
| $5.26B | |
| $4.24B |
- $28.12B
- $20.10B
- $14.56B
- $9.13B
- $5.74B
- $5.26B
- $4.24B
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation